drugset / Trial / NCT00035607

Chemotherapy Related Anemia

NCT00035607

Phase 2 Completed 120 enrolled Amgen
RandomizedParallel-groupOpen-labelSupportive care

Summary

This study is investigating darbepoetin alfa for the treatment of anemia in patients with non-myeloid cancers who are receiving chemotherapy. Darbepoetin alfa is a recombinant protein that stimulates the production of red blood cells. In this study, darbepoetin alfa will be administered as either an injection under the skin (subcutaneously) or directly into a vein (intravenously).

Timeline

Start
2001-12
Primary completion
2002-12
Completion
2003-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Darbepoetin alfa Protein / enzyme biologic 4.5 ug/kg Subcutaneous

Indications